Safety and Tolerability of Oral Islatravir Once Monthly as Pre-Exposure Prophylaxis in Cisgender Men and Transgender Women Who Have an Elevated Likelihood of HIV-1 Exposure: Results From the IMPOWER-24 Randomized Phase 3 Study

By afschroeder • March 14, 2026

Landovitz RJ, Pinedo Y, Hinestrosa F, Crofoot GE, Brinson C, Buchbinder S, Molina JM, Gravett RM, Brock JB, Ramgopal MN, Rosengren AL, Ofotokun I, Valdez Madruga J, Liegeon G, Panchia R, Supparatpinyo K, Avihingsanon A, Creticos C, Swaminathan S, Doblecki-Lewis S, Rodriguez J, Siegel M, Oka S, Puthanakit T, Grinsztejn B, Sanders EJ, Lama JR, Lombaard J, Ndlovu N, Hwang P, Du J, Jackson B, Homony B, Evans B, Sklar P, Robertson MN, Plank RM. Safety and Tolerability of Oral Islatravir Once Monthly as Pre-Exposure Prophylaxis in Cisgender Men and Transgender Women Who Have an Elevated Likelihood of HIV-1 Exposure: Results From the IMPOWER-24 Randomized Phase 3 Study. Clin Infect Dis. 2026 Mar 14:ciag171. doi: 10.1093/cid/ciag171. Epub ahead of print. PMID: 41830344.

Tags: cisgender men, HIV-1 prevention, Infectious Diseases, islatravir, PrEP, Publications, Transgender women

Detection of Marburg Virus Antibodies 25 Years After Outbreak in Watsa, Democratic Republic of the Congo

Merritt S, Mukadi PK, Kompany JP, Halbrook M, Musene K, Martin SA, Beya M, Tambu M, Wong TAS, Muyembe-Tamfum JJ, Kaba DK, Lehrer AT, Kindrachuk[...]

Navigating Masculinities: An Exploration of Peer Coaching, Health Behaviors, and Mortality Risks Among Men in Tuberculosis and HIV Interventions in South Africa

Rutt K, DeVos L, Gala K, Njama T, Fosi M, Mhaleni Z, Daniels J, Medina-Marino A. Navigating Masculinities: An Exploration of Peer Coaching, Health Behaviors,[...]

Human antibody repertoire among kidney donors with and without HIV

Zhu X, Morgenlander WR, Brown DM, Eby Y, Morsheimer M, Odim J, Bagnasco SM, Rana MM, Florman SS, Friedman-Moraco RJ, Stock PG, Gilbert AJ, Mehta[...]